**Appendix Table E58. Results from studies assessing the ability of VASP to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., HPR+ or HPR-)** | **No. with outcome status within phenotype group** | **Cut-off** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Siller-Matula,  2009{Siller-Matula, 2009 234 /id}  19135705  Austria  NR | Clopidogrel 75 mg MD | VASP | VASP | PRI as measured by VASP | 24 hrs after PCI | Platelet reactivity index ≥ 69% by VASP (? Low efficiency) | Platelet reactivity index ≥ 69% by VASP (? Low efficiency) | 1 | NR | NR | NR | 0.27 (fisher’s exact calculated from data) | NR | NR | Fig 1B |
|  |  |  |  |  |  | Platelet reactivity index ≥ 69% by VASP (? Low efficiency) | Platelet reactivity index <69% | 7 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Platelet reactivity index <69% by VASP | Platelet reactivity index ≥ 69% | 0 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Platelet reactivity index <69% by VASP | Platelet reactivity index <69% by VASP | 22 | NR | NR | NR | NR | NR | NR |  |
| Kalantzi 2011{Kalantzi, 2011 19 /id}  21255245  Greece  NR | Clopidogrel 300 mg loading & 75 mg/d | VASP at Day 5 | Nonresponder by VASP | PRI ≥ 50% | 30 days | Nonresponder | Nonresponder | 3 | PRI≤50% | NR | NR | 0.01264 (fisher’s exact calculated from data) | N | NO |  |
|  |  |  |  |  |  | Nonresponder | Responder | 12 | NR | NR | NR | NR | NR | NR | NR |
|  |  |  |  |  |  | Responder | Nonresponder | 0 | NR | NR | NR | NR | NR | NR | NR |
|  |  |  |  |  |  | Responder | Responder | 46 | NR | NR | NR | NR | NR | NR | NR |
| Bjelland, 2010{Bjelland, 2010 42 /id}  20727659  Norway  NR | Clopidogrel 300-600 mg LD + 75 mg MD | VASP Platelet reactivity index < 0.5 at Day 1 | Satisfactory Clopidogrel effect | Platelet reactivity index < 0.5 | Day 3 | Satisfactory (PRI <0.5) at day 1 | Satisfactory (PRI <0.5) at day 3 | 0 | 0.5 | NR | NR | Not calculable as no patients had PRI<50% at baseline | NR | NR |  |
|  |  |  |  |  |  | Satisfactory (PRI ≥0.5) at day 1 | Unsatisfactory (PRI ≥0.5 at day 3) | 0 |  |  |  |  |  |  |  |
|  |  |  |  |  |  | Unsatisfactory (PRI ≥0.5) at day 1 | Unsatisfactory (PRI ≥0.5) at day 3 | 20 |  |  |  |  |  |  |  |
|  |  |  |  |  |  | Unsatisfactory (PRI ≥0.5) at day 1 | Satisfactory (PRI <0.5 at day 3) | 5 |  |  |  |  |  |  |  |
| Djukanovic, 2008{Djukanovic, 2008 163 /id}  18719318  Serbia  NR | clopidogrel 75 mg + Aspirin 100 mg | VASP phosphorylation | Good response | PRI≤50% | 7 days | Rapid response | Good response | NR | NR | NR | NR | NR | NR | NR | Text mentions that “all the patients with rapid response still had PRI  ≤50% (good responders) on day 7” but actual numbers in each outcome group can only be obtained from digitized Fig 2B which is not clear |
|  |  |  |  |  |  |  | Bad response | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Not Rapid response | Good response | NR | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  |  | Bad response | NR | NR | NR | NR | NR | NR | NR |  |
| Palmerini , 2010{Palmerini, 2010 81 /id}  19604542  Italy  DOUBLE | Clopidogrel 300 mg LD + 75 mg MD | VASP | VASP | PRI>50% at 1 month | 1 month | Poor responder | Poor responder | 10 | NR | NR | NR | 1.0 (fisher’s exact calculated from data) | NR | NR |  |
|  |  |  |  |  |  | Poor responder | Normal responder | 11 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Normal responder | Poor responder | 2 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Normal responder | Normal responder | 1 | NR | NR | NR | NR | NR | NR |  |
|  | Clopidogrel 300 mg LD + 150 mg MD | VASP | VASP | PRI>50% at 1 month | 1 month | Poor responder | Poor responder | 3 | NR | NR | NR | 0.54 (fisher’s exact calculated from data) | NR | NR |  |
|  |  |  |  |  |  | Poor responder | Normal responder | 17 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Normal responder | Poor responder | 1 | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Normal responder | Normal responder | 3 | NR | NR | NR | NR | NR | NR |  |